COSCIENS Biopharma Inc. Current Liabilities
COSCIENS Biopharma Inc. (CSCIF) had Current Liabilities of $3.61 million as of 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Notes
ifrs-full:CurrentLiabilities · last filed 2026-03-25
- 2025-12-31: Current Liabilities $3.61M.
- 2025-09-30: Current Liabilities $3.98M.
- 2025-06-30: Current Liabilities $5.53M.
- 2025-03-31: Current Liabilities $7.06M.
| Period end | Current Liabilities | Current Liabilities as first filed |
|---|---|---|
| 2025-12-31 | $3.61M 20-F · filed 2026-03-25 | |
| 2025-09-30 | $3.98M 6-K · filed 2025-11-12 | |
| 2025-06-30 | $5.53M 6-K · filed 2025-08-14 | |
| 2025-03-31 | $7.06M 6-K · filed 2025-05-13 | |
| 2024-12-31 | $7.22M 20-F · filed 2026-03-25 | |
| 2024-09-30 | $8.17M 6-K · filed 2024-11-12 | |
| 2024-06-30 | $9.90M 6-K · filed 2024-08-13 | |
| 2024-03-31 | $5.25M 6-K · filed 2024-05-16 | |
| 2023-12-31 | $1.31M 20-F · filed 2025-04-09 | $4.54M 20-F · filed 2024-03-27 |
| 2023-09-30 | $4.23M 6-K · filed 2023-11-09 | |
| 2023-06-30 | $4.08M 6-K · filed 2023-08-09 | |
| 2023-03-31 | $6.43M 6-K · filed 2023-05-09 | |
| 2022-12-31 | $7.04M 20-F/A · filed 2024-07-17 | |
| 2022-09-30 | $5.97M 6-K · filed 2022-11-03 | |
| 2022-06-30 | $6.41M 6-K/A · filed 2022-08-04 | |
| 2022-03-31 | $5.67M 6-K · filed 2022-05-11 | |
| 2021-12-31 | $7.77M 20-F/A · filed 2024-02-15 | |
| 2021-09-30 | $4.78M 6-K · filed 2021-11-04 | |
| 2021-06-30 | $4.55M 6-K · filed 2021-08-05 | |
| 2021-03-31 | $4.95M 6-K · filed 2021-05-05 | |
| 2020-12-31 | $4.74M 20-F · filed 2022-03-29 | $5.01M 40-F · filed 2021-03-25 |
| 2020-09-30 | $1.80M 6-K · filed 2020-11-05 | |
| 2020-06-30 | $2.53M 6-K · filed 2020-08-06 | |
| 2020-03-31 | $3.19M 6-K/A · filed 2020-05-11 | |
| 2019-12-31 | $5.66M 40-F/A · filed 2021-03-29 | |
| 2019-09-30 | $5.47M 6-K · filed 2019-11-07 | |
| 2019-06-30 | $7.02M 6-K · filed 2019-08-13 | |
| 2018-12-31 | $5.60M 20-F · filed 2020-03-31 | |
| 2017-12-31 | $5.77M 20-F · filed 2019-04-01 | |
| 2016-12-31 | $4.20M 20-F · filed 2018-03-28 |